An article in PM360 on July 7, 2015, includes a discussion with BRI and Immune Tolerance Network (ITN) Director Gerald Nepom, MD, PhD, on an ITN study of Alefacept, an immunosuppressive biologic drug that appears to stem the progression of new-onset type 1 diabetes more than a year after therapy is stopped. For more information, visit ADA: Alefacept slows progress of type 1 diabetes 15 months post-treatment.